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Abstract
Background and Objectives Recently, the osteoporosis
treatment has attracted attention, and several drugs have
been developed. Among these, bisphosphonates (BPs),
parathyroid hormone (PTH) and anti-receptor activator of
nuclear factor kappa B ligand (RANKL) monoclonal
(MAb) denosumab (DMAb) are the major osteoporosis
agents. Several studies demonstrated that the effect of
osteoporosis agents is evaluated by lumar or hip dual
energy X-ray absorptiometry (DXA). However, private
clinic commonly use the radial DXA. On the other hand,
rheumatoid arthritis (RA) is sometimes associated with
osteoporosis but there is no established treatment approach.
In addition, glucocorticoids (GCs) are often used in the
treatment of RA and sometimes induce osteoporosis. The
present study assessed the effect of DMAb on osteoporosis
in patients divided into RA and RA ? GC patients by radial
DXA.
Patients The therapeutic effect of denosumab was assessed
in female osteoporosis patients using radial dual-energy
X-ray absorptiometry (radial DXA) in three groups: those
with postmenopausal osteoporosis (PO group), PO with
rheumatoid arthritis (RA group), and PO with RA receiving
glucocorticoids (RA ? GC group).
Methods In total, 427 PO patients 60 years of age or older
with a young adult mean value of\70 %, as determined by
radial DXA, were treated with denosumab. The denosumab
treatment group comprised a PO group (n = 205), RA
group (n = 156), and RA ? GC group (n = 66). The
control group comprised a PO group (n = 44) and RA
group (n = 33) who received oral bisphosphonate. Bone
mineral density (BMD) was determined by using radial
DXA. The bone turnover marker type I collagen cross-
linked N-telopeptide (NTx) was also measured.
Results and Conclusions Radial DXA revealed a signifi-
cant increase in BMD in the denosumab treatment group
but not in the bisphosphonate treatment group. The onset of
an increase in BMD with denosumab was slower in the RA
group than in those without RA. The effect of denosumab
in preventing increased NTx levels was smaller in the RA
and RA ? GC groups than in the PO group. Adherence to
denosumab treatment was statistically significantly greater
than for bisphosphonate treatment.
Key Points
Unlike bisphosphonates, the therapeutic effect of
denosumab can be assessed using radial dual-energy
X-ray absorptiometry (radial DXA) in clinics.
Radial DXA revealed the efficacy of denosumab in
rheumatoid arthritis (RA) and RA ? glucocorticoid
groups that responded poorly to bisphosphonate
treatment.
Adherence to denosumab treatment was significantly
higher than that for bisphosphonate treatment.
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1 Introduction
In recent years, the treatment of osteoporosis has become a
focus of attention, and many therapeutic agents have been
developed [1]. Among these, bisphosphonates, parathyroid
hormone (PTH) and the anti-receptor activator of nuclear
factor-jB ligand (RANKL) monoclonal antibody (MAb)
denosumab are major osteoporosis agents. Several studies
have demonstrated that the effect of bisphosphonates and
PTH is not detected by radial dual-energy X-ray absorp-
tiometry (DXA) (except for one report), during the effect of
denosumab is confirmed [2–5]. Radial DXA was selected
for use as it determines the bone mineral density (BMD) of
cortical bone rather than trabecular bone and age-related
bone loss is more common in cortical bone [6]; in addition,
radial DXA is more commonly used in clinics [7].
Rheumatoid arthritis (RA) is commonly associated with
osteoporosis but there is no established treatment approach.
Moreover, glucocorticoids are often used as a treatment for
RA and sometimes induce osteoporosis.
2 Patients and Methods
A case-control study was conducted in which the study
population comprised 427 female osteoporosis patients
60 years of age or older who received subcutaneous injec-
tion of denosumab 60 mg every 6 months between October
2013 and January 2016 and had a young adult mean (YAM)
value of\70 %. To prevent hypocalcemia associated with
denosumab treatment, all patients received an oral vitamin
D3 preparation (cholecalciferol 0.01 mg/day or eldecalcitol
0.75 lg/day) as per the package insert of denosumab.
Assessment was performed separately for the three groups:
patients with postmenopausal osteoporosis (PO) (PO group),
patients with PO with RA (RA group), and PO patients with
RA receiving glucocorticoids (RA ? GC group) (gluco-
corticoids were taken for at least 4 weeks until immediately
before the start of the study). Patients with secondary
osteoporosis probably due to other diseases such as cancer
metastatic to bone and metabolic disorders were excluded
from the study. All RA patients studied met the 1987
American College of Rheumatology criteria [8]. The control
group consisted of 78 patients retrospectively sampled from
those who had received an oral bisphosphonate every
4 weeks (minodronate 50 mg) or once a month (risedronate
75 mg) for the treatment of osteoporosis and provided
written informed consent. Patient selection was matched to
the denosumab treatment group (age C60 years, YAM value
\70 %, observation period October 2013 to January 2016).
No patient treated with glucocorticoids was in the control
group. Similar to the denosumab treatment group, assess-
ment was performed separately for the PO (44 patients) and
RA (34 patients) bisphosphonate groups. In the control
group, as with the denosumab treatment group, patients with
secondary osteoporosis were excluded and patients were
eligible for inclusion if they were 60 years of age or older
and had a YAM value of\70 %; no patients in the bis-
phosphonate group had received glucocorticoid treatment.
A total of 427 female osteoporosis patients were
treated with denosumab: 205 in the PO group, 156 in the
RA group, and 66 in the RA ? GC group. All patients in
the RA ? GC group received glucocorticoids at a dose
of B5 mg/day (1–5 mg/day). Of the female osteoporosis
patients who had received bisphosphonate treatment
after providing informed consent for participation in
previous clinical studies, 78 could be matched with those
in the denosumab treatment group for age and YAM
value; 44 and 34 were classified in the PO and RA
groups, respectively. However, no patients in the bis-




DMAb (n = 427)a BP (n = 78)b p value
Age 69.2 ± 10.3 67.9 ± 8.4 NS
Weight (kg) 57.1 ± 10.8 56.3 ± 12.7 NS
BMI (kg/m2) 26.2 ± 8.6 28.7 ± 18.4 NS
% YAM 54.1 ± 13.0 56.3 ± 13.8 NS
NTX (nmolBCE/mmolCr) 64.7 ± 25.0 66.2 ± 31.1 NS
Data are presented as mean ± standard error
BMI body mass index, BP bisphosphonate-treated group, DMAb denosumab-treated group, nmolBCE/
mmolCr nmol Bone Collagen Equivalents/nmol creatinine, NS not statistically significant, PO patients with
postmenopausal osteoporosis, RA osteoporosis patients with rheumatoid arthritis, RA ? GC osteoporosis
patients with rheumatoid arthritis taking glucocorticoids, NTX type I collagen cross-linked N-telopeptide,
YAM young adult mean
a PO (n = 205), RA (n = 156), RA ? GC (n = 66)
b PO (n = 44), RA (n = 34)
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In accordance with pre-treatment YAM and urine type I
collagen cross-linked N-telopeptide (NTx) values, the
denosumab group was divided into three subgroups and the
bisphosphonate group was divided into two subgroups.
There is no statistical difference for YAM between any two
groups, and no statistical difference was found for urine
NTx among any two groups except for between the PO and
RA ? GC groups taking denosumab (Fig. 1). It is well-
known that glucocorticoids strongly induce bone resorption
and subsequently influence the NTx level; the difference in
the RA ? GC group may be due to this effect.
All RA patients enrolled in the study showed remission
or a low 28-joint Disease Activity Score–erythrocyte sed-
imentation rate (DAS28-ESR) of\3.2 for 4 weeks before
the start of denosumab treatment [9]. The dosage of both
conventional systemic disease-modifying antirheumatic
drugs (csDMARDs) and biological DMARDs (bDMARDs)
in addition to glucocorticoids remained unchanged
throughout the study period. Those patients who required
changes in or discontinuation of antirheumatic therapy with
glucocorticoids, csDMARDs, and bDMARDs because of
changes in RA status or adverse reactions were excluded
from the study. No patients in the bisphosphonate group
required changes in their RA treatment. The objective of
the present study was to assess the therapeutic effect of
denosumab by radial DXA, and those patients who could
not meet this objective, or who dropped out for reasons
other than those related to the effect of denosumab or the
response to denosumab, were excluded. The content of the
study was explained to all patients participating in the
study and written informed consent was provided in
advance. This study was conducted according to the prin-
ciples of the Declaration of Helsinki.
BMD was determined by radial DXA (DCS-600EXV;
Hitachi AlokaMedical, Japan) every 24 weeks after the start
of the study. The change in BMD between before treatment
and after treatment (DBMD) was calculated for each patient
group to compare the effect of denosumab (Eq. 1):
DBMD ¼ radial DXA value for each week½ 
 radial DXA value at the start of treatment½ : ð1Þ
For the denosumab treatment group, assessment of a
marker of bone turnover was also performed. Levels of the
marker of bone resorption, NTx, weremeasured in the second
morning urine (enzyme-linked immunosorbent assay: nmol
Bone Collagen Equivalents/nmol creatinine) every 24 weeks
after the start of denosumab treatment. Percentage NTx
(%NTx) values were calculated to compare the effect of
denosumab in the patient groups as follows (Eq. 2):
%NTx=
NTx value for each week NTx value at the start of treatment
NTx value at the start of treatment
 100:
ð2Þ
Denosumab continuation was estimated using the
Kaplan–Meier method and compared using a log-rank test
(Mantel–Cox test). The last observation carried forward
method was used in each analysis. Results are expressed as
mean ± standard deviation or standard error (SE). This
study deals with the treatment plan approved by the
Institutional Review Board of Matsubara Mayflower
Hospital (No. 177) (Kato city, Hyogo, Japan). Verbal
informed consent was obtained from each patient to use their
clinical data. All analysis proportions were analyzed for
treatment differences with the Chi-square test and
continuous variables were compared with Student’s t test.
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a bFig. 1 Patient baseline bone
mineral density (a) and urine
NTx (b). There is no statistical
difference in % YAM among
any two groups (a). There is no
statistical difference in urine
NTx among any two groups
except for between the PO and
RA ? GC groups within the
DMAb group (b). Bars indicate
the standard deviation. BP
bisphosphonate, DMAb





arthritis, RA ? GC osteoporosis
patients with rheumatoid
arthritis taking glucocorticoids,
YAM young adult mean
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3 Results
3.1 Changes in Bone Mineral Density as Determined
by Radial Dual-Energy X-Ray Absorptiometry
After Denosumab Treatment
There were statistically significant differences in the
increase in BMD as determined by radial DXA between
denosumab and bisphosphonate treatments (p\ 0.01). No
increase in BMD was observed in the bisphosphonate
treatment group, whereas BMD was found to increase over
time in the denosumab treatment group (administration
every 6 months). The therapeutic effect of denosumab was
noted in each of the PO, RA, and RA ? GC groups.
However, the effect was slower in onset in the RA and
RA ? GC groups than in the PO group. At week 52, sig-
nificant differences were found between the increase in
BMD between the PO group and the other groups (Fig. 2).
All denosumab-treated patients received oral cholecal-
ciferol or eldecalcitol as a vitamin D3 preparation in
accordance with their hepatic or renal condition. There is
no statistical difference between patients using cholecal-
ciferol or eldecalcitol in DBMD at 102 weeks (3.0 ± 0.6
vs. 3.2 ± 0.8 [mean ± SE]).
3.2 Changes in Urinary Type I Collagen Cross-
Linked N-Telopeptide Levels After the Start
of Denosumab Treatment
Analysis of the rate of change (%) in the levels of NTx
showed that bone resorption was rapidly inhibited in the
PO group after the start of denosumab treatment and that
the inhibitory effect lasted until the end of the observation
period at week 102. The inhibitory effect of denosumab on
bone resorption was smaller in the RA and RA ? GC
groups than in the PO group. The effect of denosumab in
preventing an increase in NTx levels was statistically sig-
nificantly greater in the PO group than in the other groups
up to week 78 (Fig. 3).
3.3 Adherence to Denosumab or Bisphosphonate
Treatment
For both denosumab and bisphosphonate treatments,
withdrawal from the study was found to occur most fre-
quently at week 24 in the early stages of treatment.
Adherence to denosumab treatment was statistically sig-
nificantly higher than that for bisphosphonate treatment
(Fig. 4).
3.4 Adverse Reactions
One 75-year-old patient in the RA group discontinued
treatment with denosumab because of an adverse reaction
(osteonecrosis of the jaw [ONJ]). The patient was found to
have ONJ during tooth extraction at a dental clinic after
60 weeks of denosumab treatment (after the second
administration). However, she had been treated with bis-
phosphonate for 8 years before the start of denosumab
treatment, and therefore it is difficult to determine whether




























Fig. 2 Changes in BMD after the start of DMAb treatment as
determined by radial DXA (DBMD = [radial DXA value for each
week] - [radial DXA value at the start of treatment]). In the PO
group, the radial DXA value increased with the number of doses (over
time). Treatment with DMAb was also associated with increases in
the radial DXA value in the RA and RA ? GC groups. However, the
efficacy of DMAb in increasing radial DXA values was slower in
onset than in the PO group. At week 52 of DMAb treatment,
statistically significant differences were found in BMD between the
PO and RA or RA ? GC groups (p\ 0.05). Treatment with
bisphosphonate showed no increase in the radial DXA value, and
the effect of bisphosphonate was statistically significantly inferior to
that of DMAb (p\ 0.01). Data are expressed as mean ± standard
error. DBMD change in bone mineral density, BMD bone mineral
density, DMAb denosumab, PO patients with postmenopausal osteo-
porosis, RA osteoporosis patients with rheumatoid arthritis, RA ? GC
osteoporosis patients with rheumatoid arthritis taking glucocorticoids,
radial DXA radial dual-energy X-ray absorptiometry
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4 Discussion
The number of patients with osteoporosis has increased
with the aging of the population worldwide. Against this
backdrop, various therapeutic agents for osteoporosis have
recently been developed and applied clinically [1, 10].
Among many treatments for osteoporosis, bisphosphonate,
denosumab, and PTH are especially highly evidence based
and effective. These agents have been shown to increase
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Fig. 3 Changes in the urinary levels of NTx, a marker of bone
turnover, associated with denosumab treatment were marked in the
PO group. Up to week 78 of denosumab treatment, urinary NTx
levels were statistically significantly lower in the PO group
than in the RA and RA ? GC groups. %NTx =
NTx value for eachweek  NTx value at the start of treatment
NTx value at the start of treatment

100. Data are expressed as mean ± standard error. NTx type I
collagen cross-linked N-telopeptide, PO patients with post-
menopausal osteoporosis, RA osteoporosis patients with rheuma-
toid arthritis, RA ? GC osteoporosis patients with rheumatoid
arthritis taking glucocorticoids


































Fig. 4 Adherence to DMAb treatment remained higher than that for
BP treatment (Kaplan–Meier method). BP bisphosphonate, DMAb
denosumab, PO patients with postmenopausal osteoporosis, RA
osteoporosis patients with rheumatoid arthritis, RA ? GC osteoporo-
sis patients with rheumatoid arthritis taking glucocorticoids
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although radial DXA has revealed little effect for agents
other than denosumab. Given that radial DXA determines
cortical BMD and that age-related bone loss is attributed to
the porosity of cortical bone, radial DXA is of significance
[6]. Most of the clinics at which osteoporosis is often
treated use radial DXA to determine BMD. It is likely that
medical devices such as central (spine/hip) DXA and
computed tomography are not used because of cost and
space issues [7]. In this context, it is significant that we
assessed the effect of denosumab using radial DXA.
Presentation of beneficial therapeutic effect increases
patient enthusiasm for receiving treatment and enhances
adherence to the continuation of treatment. However, in
treatment with bisphosphonate or PTH, radial DXA is not
helpful to assess the therapeutic effect, which hinders
further treatment. Because denosumab inhibits bone
resorption by penetrating cortical bone through the extra-
cellular fluid [12], its effect can be adequately assessed by
radial DXA, which determines cortical BMD [3–5].
Although bisphosphonates are most widely used in the
treatment of osteoporosis, it was found that at most only
50 % of patients adhered to treatment for 1 year, partly
because of limitations such as the need for bed rest and
dietary restrictions other than fluid intake for at least
30 min after taking a bisphosphonate [13]. The result is
similar to that obtained for patients receiving bisphospho-
nates in the present study (Fig. 4). The low adherence to
bisphosphonate treatment in our study may be
attributable to the inadequate presentation of the thera-
peutic effect (Figs. 2, 4) in addition to the complex
instructions for taking a bisphosphonate.
In contrast to bisphosphonate treatment, at least 50 % of
patients receiving denosumab adhered to the treatment
even at week 102. This high adherence to denosumab
treatment could be attributable to the simplicity of treat-
ment (subcutaneous administration only every 6 months)
and presentation of the preferable therapeutic effect
(Figs. 2, 4). In addition, because denosumab is a human
MAb prepared using transgenic mice, it is a stable phar-
maceutical product with low immunogenicity [14], and
therefore causes only slight pain at the time of injection
and fewer adverse reactions. These factors may also con-
tribute to the high adherence.
Denosumab also had an effect in the RA and RA ? GC
groups, although it was slower in onset in these groups than
in the PO group (Fig. 2). A possible reason for this is that
denosumab had an insufficient inhibitory effect on bone
resorption (i.e., lowering of the NTx level) because of
increased bone resorption due to the presence of RA or the
impact of glucocorticoids in the RA and RA ? GC groups
(Fig. 3). This is the first reported attempt to assess the
effect of denosumab in RA and RA ? GC groups using
radial DXA. However, a previous report showed that
denosumab increases the BMD of both the lumbar spine
and total hip; this result may be attributable to the effect of
denosumab in reducing bone turnover by lowering the
levels of both a marker of bone formation, serum procol-
lagen 1 N-terminal peptide (P1NP), and one of bone
resorption, serum C-telopeptide type 1 (sCTx-1) [11]. In
the present study, denosumab insufficiently lowered NTx
levels in the RA and RA ? GC groups. This may be
because the presence of RA at the start of treatment
affected the levels of the marker of bone turnover; there-
fore, further investigations are needed to confirm this
hypothesis.
It should also be noted that bisphosphonates have been
shown to be effective in improving the BMD for the
lumbar spine but not the total hip in osteoporosis patients
with RA [15]. This is in marked contrast to the finding that
bisphosphonate has an effect on both the lumbar spine and
total hip in patients with PO alone [1], suggesting that
patients with PO complicated by RA may be more
refractory to treatment for osteoporosis. There is also a
report showing that bisphosphonate has an effect on the
lumbar spine and total hip in osteoporosis patients with RA
[16]. However, in this report, bisphosphonate had no effect
on the metacarpals, which are mainly composed of cortical
bone. In contrast, denosumab had an effect in the RA and
RA ? GC groups in the present study. In addition, deno-
sumab has recently been shown to be effective in the
treatment of bone erosion in patients with RA [17]. The
American College of Rheumatology recommends use of
alendronate or risedronate in the treatment of glucocorti-
coid-induced osteoporosis [18]. Our results show that
denosumab can also be recommended for osteoporosis in
RA patients and for RA patients taking glucocorticoids.
Moreover, one patient experienced ONJ during deno-
sumab treatment; however, it is difficult to determine
whether the ONJ is attributable to denosumab or bisphos-
phonate treatment. Recently, it has been reported that RA is
a risk factor for ONJ, and ONJ should be especially men-
tioned to long-term denosumab or bisphosphonate-treated
RA patients (median 69 months, range 20–130 months)
[19].
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